|
|
Article: Beacon Equity Research Initiates Coverage of Callisto Pharmaceuticals Projecting 12-Month Share Price Value to Reach $3.10; Growth Attributed to Promising R&D Programs to Treat Relapsed Cancers, Ulcerative Colitis and Biowarfare Threats.
- Article from:
- Business Wire
- Article date:
- October 4, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of novel drug therapies in the fight against hematologic cancers and other diseases and conditions, today announced that investment analyst Beacon Equity Research has initiated paid research coverage of the Company with an extensive report that projects a 12-month target share price of $3.10, a significant gain over the Company's recent share price of $1.38.
Beacon cites a number of investment highlights about Callisto's business and financial prospects, including:
--Multiple, diverse drugs in the development portfolio -- reducing Callisto's dependence on any single product or ...